Xinrong Pei

Dr. Xinrong Pei

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 December 2020 in Cosmetics
Verified
Journal Article
Open access
PDF file
ZSZhe Su
Zhe Su
FLFei-Ya Luo
Fei-Ya Luo
XPXinrong Pei
Xinrong Pei
FZFeng-Lan Zhang
Feng-Lan Zhang
SXShu-Xia Xing
Shu-Xia Xing
GWGangli Wang
Gangli Wang
In June 2020, the new “Regulations on the Supervision and Administration of Cosmetics” (CSAR) was finally issued and published in China. This is the first revision of the “Regulations on Hygiene Supervision of Cosmetics” (CHSR) since its publication in 1989. As the basic and fundamental legislation for cosmetics, CSAR has a far-reaching impact on the whole industry and also reveals new trends in scientific research work. To provide an interpretation of this regulation and help enterprises and researchers better understand the new policies, in this study, the main contents of CSAR and its regulatory system were introduced, and the major changes and background considerations were summarized, especially in the definition and scope of cosmetics, classification and categorization, ingredient management, safety evaluation, efficacy substantiation and technical evaluation work. A brief review of technical progress worldwide and a comparison of regulatory requirements were provided where necessary. Finally, new prospects of cosmetic science in China were discussed. In conclusion, CSAR will initiate a renewed and integrated regulatory system for cosmetics. Advanced concepts of supervision, encouragement of innovation, utilization of technical approaches and emphasis on scientific investigations are reflected in the regulations, which will deeply influence the development of both cosmetic products and new ingredients. With all these new challenges and opportunities, everyone involved should get prepared.

24 January 2023 in Molecules
Verified
Journal Article
Open access
PDF file
XPXinrong Pei
Xinrong Pei
FHFangyan Hu
Fangyan Hu
ZHZehui Hu
Zehui Hu
FLFeiya Luo
Feiya Luo
XLXiaoling Li
Xiaoling Li
DLDingxin Long
Dingxin Long
The prevalence of Alzheimer’s disease (AD) is significantly increasing due to the aging world population, and the currently available drug treatments cannot cure or even slow its progression. α-lipoic acid (LA) is a biological factor widely found in spinach and meat and can dissolve in both lipid and aqueous phases. In medicine, LA has been shown to reduce the symptoms of diabetic polyneuropathy, acute kidney injury, cancers, and some metabolism-related diseases. This study to proves that α-lipoic acid (LA) can stabilize the cognitive function of patients with Alzheimer’s disease (AD). BV2 cells were divided into control, LA, Aβ25–35, and LA + Aβ25–35 groups. Cell growth; IL-6, IL-1β, TNF-α, IFN-γ, SOD, GPx, CAT, ROS, NO, and iNOS secretion; Wnt-related proteins; cell apoptosis; and cell activation were examined. Here, we found that LA could effectively repress apoptosis and changes in the morphology of microglia BV2 cells activated by Aβ25–35, accompanied by the inhibition of the inflammatory response induced by Aβ25–35. The Wnt/β-catenin pathway is also involved in preventing Aβ25–35-induced cytotoxicity in microglia by LA. We found an inhibitory effect of LA on microglia toxicity induced by Aβ25–35, suggesting that a combination of anti-inflammatory and antioxidant substances may offer a promising approach to the treatment of AD.

30 July 2024 in Molecules
Verified
Journal Article
Open access
PDF file
SJShaoming Jin
Shaoming Jin
YWYaonan Wang
Yaonan Wang
XNxiao ning
xiao ning
TLTongtong Liu
Tongtong Liu
RLRuiqiang Liang
Ruiqiang Liang
JCJin Cao
Jin Cao
The aim of individuals consuming health supplements is to attain a robust state through nutritional regulation. However, some unscrupulous manufacturers, motivated by profit, fraudulently incorporate drugs or unauthorized components with therapeutic effects into the product for instant product performance enhancement. The long-term use of these products may inadvertently inflict harm on human health and fail to promote nutritive healthcare. The illegal inclusion of these substances is prevalent in kidney-tonifying and sexuality-enhancing products. Developing effective analytical methods to identify these products and screen for illegal added ingredients can effectively prevent such products from reaching and remaining on the market. A target screening method for the detection and quantification of 90 phosphodiesterase type 5 inhibitors (PDE-5is) in 5 kinds of health products was developed and validated. The type of dietary supplements varied from tablets, capsules, and protein powder to wine and beverages. Sample preparation was completed with a one-step liquid phase extraction. The screening process of 90 PDE-5is was done efficiently within 25 min by ultra-high performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS) using the dynamic multiple reaction monitoring (dMRM) technique. The LODs of 90 PDE-5is were detected at levels ranging from 25 to 85 ng/g or ng/mL. This novel targeting methodology was effective and can be applied to routine market supervision. Among 286 batches of samples, 8 batches were found to be positive. Three kinds of PDE-5is were first detected in healthy products. The screening method demonstrated herein will be a promising and powerful tool for rapid screening of PDE-5is.